REFERENCES
- Adler-Moore J, Proffitt RT. AmBisome: liposomal for-mulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 Suppl 1: 21–30.
- Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4: 179–85.
- Aoun M. Standard antifungal therapy in neutropenic patients. Int J Antimicrob Agents 2000; 16: 143–145.
- Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49 Suppl 1: 37–41.
- Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infec-tions. Clin Infect Dis 1997; 25: 43–59.
- Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662–678.
- Stevens DA, Kan VL, Judson MA, et al. Practice guide-lines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696–709.
- Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998; 55: 585–612.
- Arikan S, Rex JH. Lipid-based antifungal agents: Current status. Curr Pharm Des 2001; 7: 393–415.
- Hiemenz JW, Walsh TJ. Lipid formulations of ampho-tericin B: recent progress and future directions. Clin Infect Dis 1996; 22 Suppl 2: S133–144.
- Tollemar J, Klingspor L, Ringden O. Liposomal amphotericin B (AmBisome) for fungal infections in immuno-compromised adults and children. Clin Microbiol Infect 2001; 7 Suppl 2: 68–79.
- Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid for-mulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–618.
- Lequaglie C. Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections. J Antimicrob Chemother 2002; 49 Suppl 1: 49–50.
- Ellis M, Spence D, de Pauw B, et al. An EORTC inter-national multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treat-ment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406-12.
- Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with flu-conazole and amphotericin B. Antimicrob Agents Chemother 1995; 39: 598–601.
- Rex JH, Pappas PG, Karchmer AW, et al, and National Institute of Allergy, and Infectious Diseases Mycoses Study Group. A randomized, and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus ampho-tericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221–8.
- Kretschmar M, Hein A, Geginat G, Mueller C, Hof H, Nichterlein T. Inefficient T cell memory in the brain of mice infected with Candida albicans. J Neuroimmunol. 2000; 105: 161–8.
- Kretschmar M, Nichterlein T, Hannak D, Hof H. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Drug Res 1996; 46: 711–715.